Osteoarthritis.
Conditions
Interventions
Treatment 1: a single dose of 2 mg midazolam on Day 1 (Day 1 is the first day
of administration of the study compound)
Treatment 2: a single dose of 300 mg GLPG1972 once daily for 10 days (from Day
Osteoarthritis
Sponsors
Galapagos NV
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: healthy male volunteers 18 - 50 years, inclusive BMI 18.0 - 30.0 kg/m2 weight at least 50 kilograms non smokers
Exclusion criteria
Exclusion criteria: Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study. Not allowed is the use of any prescribed medication, over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (e.g. St. John*s Wort), from 14 days prior to the first administration of the study compound until the post-study visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the effect of multiple oral doses of GLPG1972 (300 mg q.d.) on the single oral dose PK of midazolam (2 mg) in healthy male subjects. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the safety and tolerability of multiple oral doses of GLPG1972 administered with a single oral dose of midazolam or without midazolam in healthy male subjects. | — |
Countries
The Netherlands
Outcome results
None listed